Daratumumab, a monoclonal antibody targeting CD38, has been approved for use with standard myeloma regimens. An evaluation of subcutaneous daratumumab combined with bortezomib, lenalidomide, and ...

RIO DE JANEIRO — The addition of daratumumab to lenalidomide maintenance therapy following autologous stem cell transplant (ASCT) significantly improves rates of achieving minimal residual ...

One hundred twenty-two patients in the Rd arm who received subsequent therapy received daratumumab. Sixty-six patients in the Rd arm received subsequent single-agent daratumumab after disease ...

Daratumumab (Darzalex, Janssen) in combination with lenalidomide and dexamethasone is indicated for 'the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for ...

A second study will evaluate the treatment and financial burden and quality of life of a program of subcutaneous daratumumab administered at home. When multiple therapeutic combinations are listed ...

The approval is for daratumumab SC in combination with bortezomib, lenalidomide, and dexamethasone (daratumumab-VRd) for the treatment of adult patients with newly diagnosed multiple myeloma.

Johnson & Johnson ($JNJ) and Genmab have played another card in their deck of data on the multiple myeloma blockbuster contender daratumumab, spelling out some ...

Daratumumab is a human IgGκ monoclonal antibody that targets CD38, which is highly expressed on myeloma cells and other hematopoietic cell types. 5,6 Daratumumab has direct and indirect antitumor ...

CASTOR was a multicenter, randomized, open-label, phase III study during which eligible patients with ≥ 1 line of prior therapy were randomly assigned to Vd (up to eight cycles) with or without ...

2.1 Daratumumab (Darzalex, Janssen) is indicated 'in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior ...